Patents by Inventor Yonglai Yang

Yonglai Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200039934
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: March 11, 2019
    Publication date: February 6, 2020
    Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Patent number: 10280141
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 7, 2019
    Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Publication number: 20180194726
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 12, 2018
    Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Patent number: 9856217
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 2, 2018
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Publication number: 20170334850
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: June 1, 2017
    Publication date: November 23, 2017
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA, Venkat KUSUKUNTLA
  • Patent number: 9708261
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 18, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Publication number: 20160368871
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 22, 2016
    Inventors: Anthony Alexander MCKINNEY, Franklin BYMASTER, Walter PISKORSKI, Fred J. FLEITZ, Yonglai YANG, David A. ENGERS, Valeriya SMOLENSKAYA
  • Publication number: 20160136148
    Abstract: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a-vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 19, 2016
    Applicant: NOVEN THERAPEUTICS, LLC
    Inventors: David A. Engers, Yonglai Yang, Stephen Parent, Travis Houston, Bruce Charles Friedman
  • Patent number: 9211290
    Abstract: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 15, 2015
    Assignee: NOVEN THERAPEUTICS, LLC
    Inventors: David A. Engers, Yonglai Yang, Stephan Parent, Travis Houston, Bruce Charles Friedman
  • Publication number: 20140187582
    Abstract: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 3, 2014
    Inventors: David A. ENGERS, Yonglai YANG, Stephan PARENT, Travis HOUSTON, Bruce Charles FRIEDMAN
  • Publication number: 20130158264
    Abstract: Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.
    Type: Application
    Filed: June 23, 2011
    Publication date: June 20, 2013
    Inventors: Arlindo L. Castelhano, David A. Enger, Jason A. Hanko, Josef A. Rechka, Jing Teng, Yonglai Yang
  • Patent number: 8424200
    Abstract: An electromagnetic interference (EMI) shielding material includes a matrix of a dielectric or partially conducting polymer, such as foamed polystyrene, with carbon nanotubes or other nanostructures dispersed therein in sufficient concentration to make the material electrically conducting. The composite is formed by dispersing the nanotube material in a solvent in which the dielectric or partially conducting polymer is soluble and mixing the resulting suspension with the dielectric or partially conducting polymer. A foaming agent can be added to produce a lightweight foamed material. An organometallic compound can be added to enhance the conductivity further by decomposition into a metal phase.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: April 23, 2013
    Assignee: University of Virginia Patent Foundation
    Inventors: Mool C. Gupta, Yonglai Yang, Kenneth L. Dudley, Roland W. Lawrence
  • Publication number: 20100000770
    Abstract: An electromagnetic interference (EMI) shielding material includes a matrix of a dielectric or partially conducting polymer, such as foamed polystyrene, with carbon nanotubes or other nanostructures dispersed therein in sufficient concentration to make the material electrically conducting. The composite is formed by dispersing the nanotube material in a solvent in which the dielectric or partially conducting polymer is soluble and mixing the resulting suspension with the dielectric or partially conducting polymer. A foaming agent can be added to produce a lightweight foamed material. An organometallic compound can be added to enhance the conductivity further by decomposition into a metal phase.
    Type: Application
    Filed: December 19, 2006
    Publication date: January 7, 2010
    Applicants: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
    Inventors: Mool C. Gupta, Yonglai Yang, Kenneth L. Dudley, Roland W. Lawrence